Eszopiclone has been discontinued (DEA controlled substance, schedule IV). | It is a nonbenzodiazepine and active stereoisomer of zopiclone with hypnotic and sedative activity and without significant anxiolytic activity. Eszopiclone is able to bind to and activate the omega-1 subtype of the alpha subunit of the gamma-aminobutyric acid-benzodiazepine GABA receptor complex (GABA-A), a chloride ionophore complex in the central nervous system (CNS). This leads to the opening of chloride channels, causing hyperpolarization, inhibition of neuronal firing, and enhancement of the inhibitory effect of GABA. This eventually leads to a hypnotic effect and allows for an induction of sleep. References: Inoue Y, Kamijo A, Nagai R. Patient Background Factors Affecting the Therapeutic Outcomes in Response to Eszopiclone in Adult Patients with Chronic Insomnia: A Post Hoc Analysis of a Double-Blind Phase III Study in Japan. J Clin Sleep Med. 2015 Oct 15;11(10):1171-8. doi: 10.5664/jcsm.5094. PubMed PMID: 26094929; PubMed Central PMCID: PMC4582058.

纯度：≥98%

CAS：138729-47-2